M&A Deal Summary

Ampersand Biomedicines Acquires AbCheck

On January 3, 2024, Ampersand Biomedicines acquired life science company AbCheck from Affimed Therapeutics AG

Acquisition Highlights
  • This is Ampersand Biomedicines’ 1st transaction in the Life Science sector.
  • This is Ampersand Biomedicines’ 1st transaction in Czech Republic.

M&A Deal Summary
Date 2024-01-03
Target AbCheck
Sector Life Science
Buyer(s) Ampersand Biomedicines
Sellers(s) Affimed Therapeutics AG
Deal Type Divestiture

Target

AbCheck

Plzen, Czech Republic
AbCheck discovers and optimizes human therapeutic antibodies with one of the industry’s most versatile technology platforms. AbCheck was founded in 2009 and is based in Plzen, Czech Republic.

Search 200,500 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Ampersand Biomedicines

Boston, Massachusetts, United States
Category Company
Founded 2021
Sector Medical Products
DESCRIPTION

Ampersand Biomedicines is a multi-product platform company developing smarter medicine products. Ampersand Biomedicines was founded in 2021 and is based in Boston, Massachusetts.

DEAL STATS #
Overall 1 of 1
Sector (Life Science) 1 of 1
Type (Divestiture) 1 of 1
Country (Czech Republic) 1 of 1
Year (2024) 1 of 1

Seller(S) 1

SELLER

Affimed Therapeutics AG

Heidelberg, Germany
Category Company
Sector Life Science
DESCRIPTION

Affimed Therapeutics AG develops Human antibody therapeutics.

DEAL STATS #
Overall 1 of 1
Sector (Life Science) 1 of 1
Type (Divestiture) 1 of 1
Country (Czech Republic) 1 of 1
Year (2024) 1 of 1
Mergr

Product

Company

Legal